NCT02689141 2020-06-11
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Phase 2 Completed
German CLL Study Group
Pharmacyclics LLC.
Pharmacyclics LLC.
Pharmacyclics LLC.
Pharmacyclics LLC.